Open AccessLarger Therapeutic Window for Steroid versus VEGF-A Inhibitor in Inflammatory Angiogenesis: Surprisingly Similar Impact on Leukocyte Infiltration
Author(s) -
Shintaro Nakao,
Souska Zandi,
Nuria Lara-Castillo,
Mahdi Taher,
Tatsuro Ishibashi,
Ali HafeziMoghadam
Publication year - 2012
Publication title -
investigative ophthalmology and visual science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.935
H-Index - 218
eISSN - 1552-5783
pISSN - 0146-0404
DOI - 10.1167/iovs.11-8114
Subject(s) - bevacizumab , angiogenesis , dexamethasone , medicine , vascular endothelial growth factor , cancer research , neovascularization , pharmacology , endocrinology , chemotherapy , vegf receptors
The current treatments against inflammatory angiogenesis are steroids and anti-VEGF-A, such as dexamethasone and bevacizumab, respectively. However, the therapeutic windows for dexamethasone and bevacizumab against inflammatory angiogenesis are unknown.